Enanta Pharmaceuticals INC 8-K filings

Enanta Pharmaceuticals has entered into an Open Market Sale Agreement to offer and sell up to $75 million of its common stock through Jefferies LLC.

Enanta Pharmaceuticals announced the advancement of its zelicapavir clinical development program for Respiratory Syncytial Virus (RSV), including plans for registrational trials in high-risk adults and pediatric patients.

Enanta Pharmaceuticals reported its fiscal second quarter 2026 financial results, highlighting progress in its immunology and virology pipelines, alongside updates on ongoing litigation.

Enanta Pharmaceuticals' patent infringement lawsuit against Pfizer regarding Paxlovid is moving forward with oral arguments scheduled for May 11, 2026, at the Federal Circuit.

Enanta Pharmaceuticals' stockholders approved an increase of 1.6 million shares to its 2019 Equity Incentive Plan and re-elected two Class I directors at its Annual Meeting.

Enanta Pharmaceuticals announced improved fiscal year 2025 financial results, positive clinical data for its RSV programs, and advanced two immunology candidates, extending its cash runway into fiscal 2029.

Enanta Pharmaceuticals, Inc. announced a public offering of 6.5 million common shares at $10.00 each, expecting net proceeds of approximately $60.6 million.

Enanta Pharmaceuticals announced positive topline data from its Phase 2b study of zelicapavir for respiratory syncytial virus (RSV) in high-risk adults, supporting advancement to Phase 3.

Enanta Pharmaceuticals announced positive topline data from its Phase 2b study of zelicapavir for respiratory syncytial virus (RSV) in high-risk adults, demonstrating clinically meaningful symptom and virology improvements.

Enanta Pharmaceuticals has appointed Harry R. Trout, III and Kathleen S. Capps as interim principal financial and accounting officers, respectively, following Paul J. Mellett's medical leave.

Enanta Pharmaceuticals has filed a patent infringement lawsuit against Pfizer Inc. in the European Union's Unified Patent Court regarding its COVID-19 antiviral, Paxlovid.

Enanta Pharmaceuticals reported fiscal third-quarter 2025 financial results, highlighting pipeline progress with key RSV data expected in September and a strong cash position.

Enanta Pharmaceuticals announces its fiscal second quarter results, highlighting progress in RSV and immunology programs and a strong cash position.

Enanta Pharmaceuticals' stockholders approved an amendment to the company's 2019 Equity Incentive Plan, increasing the number of shares reserved for issuance by 800,000.

Enanta Pharmaceuticals announces financial results for fiscal Q1 2025, highlighting progress in RSV and immunology programs, supported by a strong cash position.

Enanta Pharmaceuticals reports positive topline data from its Phase 2 pediatric study of zelicapavir, showing significant antiviral effects against respiratory syncytial virus (RSV).

Enanta Pharmaceuticals announced its fiscal fourth quarter and year-end results, highlighted by positive data from an RSV study and expansion of its immunology portfolio.

Enanta Pharmaceuticals reported its fiscal third quarter results, highlighted by the completion of enrollment in a key pediatric RSV study and progress in other clinical programs.

Enanta Pharmaceuticals announced its fiscal second quarter results, highlighted by progress in its RSV and immunology programs, and a cash balance of $300.3 million.

Enanta Pharmaceuticals' stockholders approved an amendment to the 2019 Equity Incentive Plan, increasing the number of shares reserved for issuance by 975,000.

Enanta Pharmaceuticals announced its fiscal first quarter 2024 results, highlighting progress in RSV clinical trials and expansion into immunology with a new program targeting chronic spontaneous urticaria.